Drug Profile
Research programme: transient receptor potential channel therapeutics - PharmEste
Alternative Names: PHE 575; TRPA1 antagonists; TRPV1 antagonistsLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator PharmEste
- Class
- Mechanism of Action TRPA1 protein inhibitors; TRPV1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Neuropathic pain; Overactive bladder; Respiratory tract disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in Italy
- 04 Nov 2017 No recent reports of development identified for research development in Respiratory-tract-disorders in Italy
- 24 May 2011 Research programme: transient receptor potential channel therapeutics - PharmEste is available for licensing as of 24 May 2011. http://www.pharmeste.com